Phase 3 N=147 Getting SMART for Pediatric Epilepsy
Epilepsy in Children
Primary: Sleep Onset Latency — 22.80; 29.99 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=998 Colorectal Cancer Screening in Alaska Native Men
Colorectal Cancer
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 11; 16; 18; 19 Participants
N/A N=27 Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading
Developmental Language Disorder · Specific Language Impairment · Language Development
Primary: Word Form Accuracy (Number of Words Correctly Recalled) in Repeated Spaced Retrieval (RSR) and Repeated Study (RS) Conditions at 5 Mins. — 4.54; 6.5; 1.46; 4.0 number of…
Phase 2 N=161 A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Change From Baseline of Nausea Severity Score — -3.55; -3.65; -3.43; -2.83 units on a scale — p=0.1350
Phase 2 N=19 Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percentage of Patients in Non-progression at 2 Months — 14.3 percentage of participants
Phase 2 N=57 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Sarcoma · Liposarcoma · Leiomyosarcoma
Primary: 12-week Progression Free Survival (PFS) — 69.6; 36.8; 52.6 percentage of participants
N/A N=1,071 BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
Breast Cancer
Primary: Number of Eligible Women Who Received Breast Cancer Risk Assessment — 8; 56; 29 Participants
N/A N=269 Cali Sin Tos Aim 2
Tuberculosis
Primary: Implementation of the mHealth Strategy to Assess Feasibility. — 112 Participants
Phase 3 N=151 Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
Brain Metastases
Primary: Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level — 23.8; 34.1; 36.6; 82.6 percentage
Phase 1 N=28 A Study in Healthy People to Compare Two Different Sifrol® Tablets
Healthy
Primary: Area Under the Concentration-time Curve of Pramipexole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3573; 3632 hour * picogram…
N/A N=65 CAPO: Continuous Glucose Monitoring in A2 Gestational Diabetes and Pregnancy Outcomes
Gestational Diabetes · Maternal Complication of Pregnancy
Primary: Composite Primary Outcome — 0; 0; 0; 0 Participants — p=1.0
Phase 1 N=36 Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Glioblastoma
Primary: Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Subjects With Recurrent or Progressive Glioblastoma Based on Evaluation of Adverse Events Summarized by…
N/A N=1,377 Behavioral and Psychological Impact of Returning Breast Density Results to Latinas
Breast Cancer
Primary: Knowledge of Breast Density as a Masking Factor at First Follow-up — 101; 104; 100 Participants — p=> 0.05
Phase 2 N=139 Efficacy and Safety on SOM3355 in Huntington's Disease Chorea
Huntington Chorea
Primary: Change in Total Maximal Chorea (TMC) Score of the UHDRS® for Subjects Not Taking Neuroleptics During the Trial (mITT - N=122) — -2.19; -2.42; -3.46 units on a scale…
N/A N=240 GamePlan4Care: Online Support for Family Caregivers
Dementia
Primary: Change From Baseline Caregiving Burden at 6 Months — -3.00; -2.75 score on a scale